Navigation Links
Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
Date:4/17/2008

ted share, on an after-tax basis)

related to COLLEAGUE infusion pumps and $19 million ($11 million, or

$0.02 per diluted share, on an after-tax basis) related to the

company's recall of heparin sodium injection vial products in the

United States.

(2) Other Income, Net in 2008 included income of $16 million

($10 million, or $0.02 per diluted share, on an after-tax basis) due

to the finalization of the net assets transferred in the divestiture

of the Transfusion Therapies (TT) business. Other Income, Net in

2007 included income of $23 million, reflecting a gain on the sale

of the TT business of $58 million less related charges of

$35 million. The after-tax impact of the gain and related charges

in 2007 was $6 million of income, or $0.01 per diluted share.

(3) Refer to page 7 for a description of the adjustment and a

reconciliation to GAAP (generally accepted accounting principles)

measures.

Non-GAAP Financial Measures: The non-GAAP financial measures contained in

this press release (pre-tax income, net income and per-share earnings,

excluding certain items) adjust for factors that are unusual or

nonrecurring. Unusual or nonrecurring items can be highly variable,

difficult to predict, and of a size that may substantially impact the

company's reported operations for a period. Management believes that

non-GAAP financial measures can facilitate a fuller analysis of the

company's results of operations, particularly in evaluating performance

period over period. Management uses these non-GAAP financial measures

internally in financial planning, to monitor business unit performance,

and in evaluating management performance. Refer to the company's filing

on Form 8-K of today's date for additional information.


'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
2. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
3. Baxter Named to Dow Jones Sustainability Index for Ninth Consecutive Year
4. Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products
5. Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
6. Baxter Kidney Patient Education Program Celebrates Tenth Anniversary
7. Baxter Receives 510(k) Clearance From FDA For V-Link With VitalShield, New Antimicrobial Intravascular Technology
8. Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit
9. Baxter International Fourth Quarter 2007 Financial Results Conference Call
10. Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials
11. Baxters Costa Rica Facility Recognized With Shingo Prize for Excellence in Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22 de enero de 2015  El Dr. Paul ... llamada a nominaciones para 2015. Este prestigioso premio reconoce ... tiene el potencial para hacer, contribuciones destacadas para la ... hasta el 15 de marzo de 2015 a través ...
(Date:1/22/2015)... 22, 2015   GenoSpace , a precision medicine software company ... the broad use of genomic, imaging and other biomedical data ... Michelle Munson , CEO of Aspera, an IBM Company, ... - http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... BOTHELL, Wash. , Dec. 24, 2014   BioLife Solutions ... manufacturer and marketer of proprietary clinical grade hypothermic storage ... thermal shipping products for cells and tissues  ("BioLife" or ... Annual Meeting of Stockholders on May 4, 2015 (the "Annual ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... Ltd. (Bovespa:,AGEN11), one of the largest provider of integrated ... to its,shareholders and investors that, on April 10, 2008, ... acquisition of 264,000 m3 of,biodiesel, for delivery between July ... was to ensure supply of the necessary volumes for ...
... Inc.,(Amex: SGN ) has confirmed that it has ... Executive Officer, Dr. Lowell T. Harmison, has,scheduled a webcast ... Dr. Harmison stated: "Now that Signalife has closed filing ... shipping,product, I am pleased to provide direction on new ...
... SIAL ), will hold its quarterly conference ... 23, 2008, at 11:00 a.m. Eastern Time,(10 a.m. ... by Thomson/CCBN and can be accessed at,Sigma- Aldrich,s ... webcast is also being distributed through the Thomson ...
Cached Biology Technology:Signalife Announces Webcast 2Signalife Announces Webcast 3Sigma-Aldrich Corporation 1st Quarter 2008 Earnings Conference Call 2
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric ... recent success of the Wocket™ smart wallet at CES 2015 in ... named as one of the "11 Hot Products at CES" in a ... CES So Far" by Newseveryday.com and "The top 10 gadgets from CES ...
(Date:1/22/2015)... 21, 2015  Analyst Report Issued by Small Cap IR. In ... that planet-wide, transactions at merchants on the leading payment cards ... of credit, debit, and prepaid cards reached 6.54 billion.  Eight ... fraudulent card usage in 2012, and credit and debit card ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... of the "Global Wearable Technologies Market and ... Overview, Trends and Forecast 2014-2020" report to ... are smart devices that can be worn on ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... definitely something to be said for first impressions. New ... can take just 20 seconds to detect whether a ... compassionate. The findings reinforce that healthy humans are ... in a tough situation. They also pave the way ...
... 90 percent of cancer deaths are caused by secondary tumors, ... To become mobile and break free from the original ... environment. Many cells have been implicated in this process, including ... collaborator in metastasis is platelets, the blood cells whose normal ...
... rare and neglected diseases that include potential treatments for ... that affects the central nervous system of newborns, a ... a rare lung disease. The six new projects are ... Rare and Neglected Diseases (TRND) program. "These projects ...
Cached Biology News:Is a stranger trustworthy? You'll know in 20 seconds 2MIT: Uncovering a key player in metastasis 2MIT: Uncovering a key player in metastasis 3NIH TRND program announces next round of drug development projects 2NIH TRND program announces next round of drug development projects 3NIH TRND program announces next round of drug development projects 4NIH TRND program announces next round of drug development projects 5
Human RXR beta/NR2B2 MAb (Clone H7341) Keywords: RXRbeta, RXRbeta, Retinoid X Receptor beta...
Human SOST Affinity Purified Polyclonal Ab...
BOND ELUT MATRIX-C18, 25 mg ...
Prepared from plasminogen by activation with immobilized human uPA...
Biology Products: